Clin Path/Transfusion Medicine/Coagulopathies/hemolymphatic Emergencies Flashcards

1
Q

Hematopoiesis

A

Production of all blood cells

Regulated by poietins, colony stimuli, interleukins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Solid cellular portion of blood components

A

red blood cells (erythrocytes),
platelets (thrombocytes)
five kinds of white blood cells (leukocytes)
– These cells are suspended within plasma, the fluid portion of blood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Erythropoietin

A

– manufactured in the kidneys
– also facilitates hemoglobin synthesis and stimulates the release of immature RBCs; aka reticulocytes, into the circulation
– increase in production is stimulated by renal hypoxia
– transported to the bone marrow, where it stimulates the proliferation and maturation of erythroid progenitor cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Erythropoiesis

Cell line up
regulated by?
how long does it take?

A

Production of RBCs
stem cells → erythroblasts → reticulocytes → erythrocytes

Regulated by EPO which is regulated by blood O2 levels in kidneys

*HYPOXIA stimulates EPO
takes 1 week for RBC maturation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Thrombopoiesis

How long does it take?

what is the precursor cell?

A

Production of Platelets
Stem cells → megakaryocyte → pieces of cytoplasm become platelets

normal platelet count in small animal patients is 200 000–800 000/mL

Can take 1 week for produciton

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Leukopoiesis

types of cells
life span

A

Production of WBCs
Granulocyte = neutrophils, eosinophils, basophils
Agranulocytes = lymphocytes (T and B), monocytes
– type of cell formed is influenced by cytokines and hormones
– destroyed by lymphatic system

life span ranges from 13-20 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

RBC structure

Life span K9/fel

A

Contains: H2O, Hb, Bi concave disc shape that creates more membrane for O2/CO2 diffusion

Lacks: Nucleus, mitochondria, ribosomes

K9 Lifespan: 120 days
Fel Lifespan: 68 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Oxyhemoglobin

A

when oxygen is bound to hemoglobin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Deoxyhemoglobin

A

when oxygen is not bound to hemoglobin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

CBC Values

A

vHb - Hemoblobin
HCT
MCV: Mean corpuscular vol; RBC avg size
MCH: Mean corpuscular Hb; Avg wt of Hb in RBC
MCHC: MCH concentration; Avg density of Hb in RBC
RDW: Red Cell Distribution width; EBC size variation
Retic %: Calc # can be overestimated w/ anemia
Absolute Retic count: # of immature RBCs; used to characterize anemia regen vs nonregen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

High MCV and low MCHC means:

A

Regenerative anemia tends to be macrocytic and hypochromic (high MCV, low MCHC)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Normal MCV and Normal MCHC means:

A

nonregenerative anemias tend to be normocytic and normochromic (normal MCV, normal MCHC).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Low MCV and Low MCHC means:

A

Iron-deficient anemia (e.g., associated with chronic gastrointestinal hemorrhage) is often microcytic and hypochromic (low MCV, low MCHC).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Dyserythropoiesis

A

– defective development of RBCs
– non-regenerative anemia, primary bone marrow dz (neoplasia)
– extra marrow suppression from systemic dz
– some toxins (sulfonamides)
– bone marrow typically required for diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Marrow examination with IMHA

A

Two major variants are encountered:
1. precursor directed immune-mediated anemia (when reticulocytes are targeted but bone marrow aspirates are still consistent with erythroid hyperplasia)
2. pure red cell aplasia, where earlier precursors are targeted with an absence of these cells on marrow examination.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

3

Treatment approach to anemia

A

therapeutics aim to address impaired DO2, support erythropoiesis, or treat underlying primary disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Treatment that Support erythropoiesis

x3

A
  1. Darbepoietin: support erythropoiesis in situations of endogenous erythropoietin deficiency
  2. Iron dextran: support erythropoiesis in iron-deficient patients
  3. Cobalamin: support erythropoiesis in hypocobalaminemic patients
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Senescene

What can exacerbate this?

A

RBC aging process
1% of old RBCs removed daily via intravascularly or extravasclularly

Oxidative Stress (free radicals) contribute to rapid RBCs aging/destruction
-exacerbated by dz/toxins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Intravascular vs Extravascular Hemolysis

where does it occur? what % is destroyed where?

A

Intravascular: accounts for 10%, Hb released into blood stream → hemglobinemia → excess unconj Hb in plasma → eliminated by kidneys

Extravascular: 90% of RBC destruction via macrophages in spleen and liver into amino acids, iron, and heme (from Hb)
-AA recycled by Liver
-Iron to bone marrow
-Heme broken into free or unconj bilirubin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What clin path finding is present in intravascular hemolysis but not extravascular?

A

Hemoglobinemia and hemoglobinuria are not seen in extravascular hemolysis since the cells are destroyed outside the blood vessels via normal mechanisms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Pathophysiology of Icterus

3 types

A

-Excessive RBC breakdown → excessive unconj bilirubin in plasma
-Unconj bilirubin exceeds Livers ability to conjugate → desposits to tissues (PRE-hepatic)
-Liver dz/dysfunction cannot handle processing unconj. bilirubin → buildup
- Bilirubin obstruction → conj bilirubin backs up into blood stream then tissues (POST- hepatic)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Regenerative Anemia

What do the RBCs typically look like?

A

– bone marrow responds appropriately by increasing red blood cell production and increased reticulocytes release
– occurs either due to hemorrhage or hemolysis → result of internal loss, external loss, destruction by way of hemolysis, or dilution
polychromasia → more immature RBCs than mature
– can be macrocytic → larger than normal OR anisocytosis → various different sizes
– peripheral metarubricytosis (nucleated red cells)
hypochromic = low hemoglobin concentration and hence appear a paler color due to the abundance of reticulocytes in circulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Two forms of reticulocytes observed in cats:

A
  1. aggregate → shorter lived and should be used to gauge regeneration in cats
  2. punctate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Metarubricytes in the face of nonregenerative anemia is:

A

an inappropriate marrow response, and reasons for bone marrow derangement should be considered (e.g., bone marrow neoplasia, heat related illness, feline leukemia).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

How long does it take for bone marrow to respond to acute blood loss?

A

– bone marrow requires time to respond to acute blood loss, and this typically takes 2–3 days in cats and 4–5 days in dogs
– anemia can be “preregenerative”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

5

Macrocytic, Normocytic Anemia

A
  1. FeLV infections with no reticulocytosis (common)
  2. Poodle macrocytosis (not anemic)
  3. Hyperthyroid cats (slight macrocytosis without anemia)
  4. Spurious with erythrocyte agglutination
  5. Spurious in cats and dogs with persistent hypernatremia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Regenerative Anemia Absolute retic count #

A

Absolute reticulocyte/PCM count:
> = 100,000/ul (dog)
> = 60,000/ul (cat)

non regen < than these #s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Non-regen, Normocytic, Normochromic anemia

A

the type of anemia in which circulating RBCs are the same size (normocytic) and have a normal red color (normochromic)
Pre-Regenerative anemia → not enough time has passed for reticulocyte generation to respond

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Non‐Regenerative Anemia

2 categories
Describe RBC appearance

A

– occurs secondary to impaired erythropoiesis associated with primary bone marrow disease or systemic disease leading to secondary extra-marrow suppression.
– Most cases of non‐regenerative anemia have normal red blood indices as they are normocytic and normochromatic
– two categories:
1. hypoproliferative anemia
2. abnormal RBCs are sequestered in the bone marrow
– red blood cells appear microcytic after Hb, iron, and RBC reserves are exhausted

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Hypoproliferative anemia

A

– bone marrow RBC production is static or reduced

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What is the best way to evaluate regeneration response?

A

the presence or absence of reticulocytes in the peripheral blood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

7

Potential causes for NNN anemia

A
  1. Chronic inflammation and neoplasia (sometimes slightly microcytic)
  2. Chronic renal disease
  3. Endocrine deficiencies
  4. Selective erythroid aplasia
  5. Aplastic and hypoplastic bone marrow
  6. Lead toxicity (may not be anemic)
  7. Cobalamin deficiency
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Non Regen Anemia: Primary Bone
Marrow Disorder

A
  1. Pure Red Cell Aplasia (PRCA)
  2. Aplastic Anemia
  3. Myelodysplastic
  4. Syndrome
  5. Myeloproliferative
  6. Diseases
  7. Myelophthisis
  8. Myelonecrosis
  9. Viral Infection
    * Parvovirus
    * (Dog/Cat)
    * FeLV (Feline)
    * FIV (Feline)
  10. Drug-Induced
  11. Hematologic Dyscrasia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

4

Non Regen Anemia: Secondary Suppression
of Bone Marrow From Systemic Disease

A

1 Chronic Inflammatory Disease
*Infection
*Inflammation
*Neoplasia
2. Chronic Renal Failure
3. Endocrine Disorder
*Hypothyroidism
*Hypoadrenocorticism
*Estrogen toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

primary failure of erythropoiesis

A

severe erythroid hypoplasia of the bone marrow occurs and precursor red cells are not produced
– uncommon, but primary failure is typically immune mediated, acquired, and may be associated with many disease conditions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Aplastic anemia: Non regen or Regenerative

A

Non-regenerative: characterized by bone marrow failure
Examples:
Estrogen induced
Drug use : antibiotics
Chemotherapy
Radiation
Infectious disease

Can be primary or secondary to another dz process: thymoma, leukemia, infection, toxicities, or renal disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Marrow infiltration

A

another form of bone marrow failure associated with
1. neoplasia
1. myelofibrosis: the replacement of bone marrow with fibrous connective tissue
1. osteopetrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Hemolysis: Non-regen or Regenerative?

A

Regenerative
Immune mediated
Neonatal isoerythrolysis
Transfusion reaction
Infectious
Heinz body anemia
Zinc toxicity
Copper toxicity
Pyruvate kinase deficiency
Phosphofructokinase deficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Impaired red cell production: Non-regen or Regenerative

A

Non-Regenerative
Immune mediated → can be both
Neoplasia → can be both
Drug induced
Inflammatory disease→ Always Non Regen
Chronic renal disease
Endocrine diseases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Bone marrow infiltration: Non-regen vs Regenerative

A

Non‐regenerative
Neoplasia
Myelofibros

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

anemia of chronic inflammatory disease

Type of anemia
suspected mediator

A

– usually mild to moderate, normocytic, normochromic, and always non‐regenerative
– decreased RBC lifespan
– suspected mediator is hepcidin, a protein produced by the liver in response to the release of IL‐6 as part of host defense against inflammatory stimuli
– Hepcidin is also produced in hypoxic or iron‐deficient states and inhibits iron export from duodenal enterocytes and macrophages, resulting in decreased iron absorption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Polycythemia

Definition and consequences

A

abnormally increased packed cell volume, red blood cell count, and hemoglobin concentration
– induces an increase in blood viscosity, particularly when the packed cell volume rises above 50–60% in dogs
polycythemia increases cardiac workload and hinders microcirculation.
– potentiates thrombosis, causes tissue hypoxia, and makes neurological complications more likely
Absolute vs Relative

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Absolute polycythemia

primary vs secondary

A

caused by an increased total RBC mass, divided into primary or secondary polycythemia
primary when the increase in red cell mass results from an abnormality of the myeloid stem cells
secondary when the increase in red cells is in response to increased levels of erythropoietin inappropriately
* ex: PDA, congenital heart defects, renal neoplasia, → local hypoxemia triggers erythropoietin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Relative polycythemia

A

hemoconcentration due to decreased plasma volume
because of the shifting of body fluids from the vascular space into the interstitial space due to dehydration, excessive external loss of body fluids, or overuse of diuretics
– ex: hemorrhagic gastroenteritis, who lose a large volume of fluids rapidly
Splenic contraction can lead to an increase in circulating red blood cells but not in the total number of red cells in dogs; this normal physiological response should not be interpreted as polycythemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q
A

Acanthocytes
spiculated red cells with a few projections
RBCs with blunt finger like projections
Injury via RBC damage traveling thru vasculature or fragile from iron deficiency
Liver dz, DIC, vasculitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

3 examples
what do these suggest?

A

Spherocyte; more disc shape than biconcave, smaller, more dense lacking central pallor
IMHA; regenerative
Oxidative injury
Coral snake
suggest immune mediate destruction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Causes x4

A

Schitocytes; RBC fragments
mechanical injury to erythrocytes, turbulent blood flow
-Vascular abnormalities; DIC, vasculitis, PSS, hemangioma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Causes x4

A

Echinocytes “Spur cells” (tiny sun)
Drugs; chemo agents, furosemide
Renal dz; glomerulonephritis
Snake envenomation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q
A

Reticulocytes; immature RBCs. Lg amounts of RNA form dark blue clumps/strands
Bone marrow respone to anemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q
A

Ghost Cells; pale RBCs due to loss of hemoglobin thru intravascular hemolysis
-IMHA
-Oxidant injury
-Snake envenomation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q
A

Basophilic stippling; numerous small blue punctuate stippling in RBCs
-Regenerative Anemia
-Lead poisoning

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

caused by;
examples x6

A

Heinz bodies; dense granuel on the edge of RBC caused by oxidative injury = hemoglobin to precipitate
Propofol; acetaminophen in cats
toxins; Onion, zinc in dogs
anticoagulant rodenticide
Skunk musk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q
A

Howell- Jolly bodies; small round dark purple dots (nucleus remnants) within RBCs
Regenerative anemia
impaired splenic function (corticosteroids/splenectomy)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q
A

Nucleated RBC - most mature nucleated RBC
present in strongly regenerative anemias

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q
A

Band Neutrophil; immature neutrophils
↑ bands present = left shift with acute or severe inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q
A

Toxic neutophilic change

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

Neutrophils

how much of count do they make up?
how do they migrate to tissues?

A

– phagocytes aka “clean up crew” that engulf micor-organisms and tissue debris
–Circulates for few hours then migrates into tissues
– most numerous circulating leukocyte in the dog and cat
– become attracted to site of potential infection or inflammation through a chemical signaling process known as chemotaxis that employs endogenous inflammatory mediators.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

Eosinophils

what % of count do they make up?
how long do they stay active?

A

Respond to histamines → allergies, anaphylaxis, parasitic infx, sometimes cancer
– ≤5% of the total WBC count
– do not stay in the circulating pool for very long and migrate into tissues within hours
– granules contain anti-inflammatory subtances
– effective against protozoas an parasitic infections

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

Basophils

what do they initiate? what do they release and in reponse to what?

A

Initiate immune/allergic responses
Release histamines in response to chemicals from mast cells
– rarest WBCs in circulation
– granules contain histamine and heparin, making these cells effective at initiating inflammation by working in conjunction with eosinophils
– Eosinophils are attracted to the site of allergic reaction by chemotactic factors released from basophilic granule
– Basophilia is most commonly associated with an allergic or hypersensitivity reaction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

Monocytes

how do they enter tissue site?
make up % of circulating WBCs

A
  • Mono-nuclear
  • Phagocytosis, process antigens
  • become macrophages → most of their phagocytosis occurs in the tissues
  • monocytes enter tissues by the process of chemotaxis.
    – after entering tissues = tissue macrophages
    – make up 5–6% of the circulating WBCs
    – mature much faster than neutrophils,
    – stay in peripheral blood longer
    – largest WBC in circulation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

Tissue macrophages

Where are they mostly found? #4

A

most prevalent in filter organs such as the liver, spleen, lungs, and lymph nodes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

Mononuclear phagocyte system (MPS)

A

Monocytes and tissue macrophages
responsible for the clean‐up of variety of microscopic debris in the body:
* cellular debris left over from inflammation and infection,
* specific antigens that have been destroyed by lymphocytes,
* other foreign substances.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

Lymphocytes

2 types

A

only WBC type w/o phagocytic capability
Memory cells of immune system
B cells = divide into plasma cells to create antibodies, Humoral immunity (lymphoid tissues)
T cells= Cytokine production, cell-mediated immunity (killing/activation/regulation) lymphoid and other tissues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

T cells

what % do they make up?
how long do they survive?
Role

A

predominant circulating lymphocyte, accounting for up to 80% of peripheral blood lymphocytes
– very long‐lived, surviving on average from 6 months to 10 years.
– there are two subtypes:
* killer T cells and helper T cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

B cells

A
  • After B lymphocytes recognizes an antigen, → transforms into a plasma cell that can release antibodies in a process called humoral immunity.
  • Plasma cells derived from B lymphocytes produce, store, and release antibodies that are known as immunoglobulins
  • Plasma cells are found in all tissue in the body, but are most common in the lymph nodes and spleen.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

Leukocytosis / Neutrophilia mechanisms

#4

A
  1. ↑ production due to inflammation (appropriate)
  2. ↑ production due to neoplasia (inappropriate)
  3. Demargination
  4. ↓ egress from circulation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

Clin path findings with Increase in production of leukocytes/neutrophils due to inflammation

A

Degenerative Left shift: absolute #s of band/immature neutrophils are > than mature ones
Leukemoid response: strong inflammatory stimulus that can mimic neoplastic response (can be seen with infx)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

Demargination

A

Corticosteriod response = stress leukogram from endongenous or exogenous steriods
–15 - 20K cells/uL
–Steriods usually clear w/i 24hrs but may take longer with prolonged use
– Epinephrine response: excitement (puppies/kittens)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

Decreased neutrophil transit time into tissues

caused by

A

Corticosteriods ↓ neutrophil transit time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

Left Shift

A

↑ immature neutrophils (bands)
– sign of inflammation or infection as the body increases neutrophil release in response to injury
Immune system responsible for causing WBCs to be released early
↑ # of monocytes
– degree of left shift corresponds with the severity of the inflammation or infection

Degenerative vs Regenerative

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

Regenerative Left Shift

A

mix of adult and immature cells
– neutrophilic leukocytosis with an increase in immature neutrophils but a larger population of mature neutrophils

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

Degenerative left shifts

A

Condition where a neutrophilic leukocytosis is present but there are more immature neutrophils than segmented neutrophils in the blood
– associated with severe disease and typically indicate a poor prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

Toxic neutrophils

what is it in response to?

A

produces in response to bacterial infx tissue necrosis
Lg # = poorprognostic indicator
– very granular appearance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

Affect of Addisons on WBCs

A

Will not see stress leukogram
–body unable to respond phisologically to stress

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

Leukopenia

A

– abnormally low white blood cell count, usually due to a decreased neutrophil count known as neutropenia (most abundant WBC)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
76
Q

Leukopenia causes

x7

A

Decrease production in bone marrow
–Viral: Parvo/Panleuk/FIV/FeLV
–Neoplasia, radiation
–Necrosis
–Drug Toxin; chemo/chloramphenicol/TMZ
–Increased utilization; fulminant inflammation, bacterial sepsis, endotoxemia
-Destruction; immune mediated
–2nd to lymphopenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
77
Q

Leukocytosis

A

elevated white blood cell count and is common in a variety of inflammatory states
– historical or clinical evidence of inflammatory disease such as pyrexia, weight loss, loss of appetite, infected wounds, and specific organ system involvement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
78
Q

Infectious Agents/Parasites that cause Leukopenia

#7

A

Histoplama
Hepatozoon
Ehrlichia
Anaplasma
Babesia
Mycoplasma
Distemper

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
79
Q

Thrombocytopenia

4 mechanisms

A

N = > 200,000 (8-15 phpf)
4 mechanisms of thrombocytopenia:
1. Sequestration; rare in animals
2. Consumption; DIC, Parvo, heatstroke, MODS
3. Destruction; ITP
4. Hypoproliferation; Bone marrow dysfunction/Liver dz = decrease thrombopoeitin production

*CKCS have abnormally low platelets due to them being oversized - idiopathetic asymptomatic thrombocytopenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
80
Q

Immune‐Mediated Thrombocytopenia results from:

x4

A

Can be due to:
1. decreased production, → myelosuppression (chemo/drugs)
1. increased consumption (e.g. a large blood clot), DIC
1. increased sequestration, → splenomegaly
1. increased destruction = ITP/DIC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
81
Q

ITP definition

A

increased platelet destruction results due to an inappropriate immune response
– either primary or secondary
– Regardless of cause ITP is a type II hypersensitivity reaction that results in destruction of circulating platelets when antiplatelet antibodies attach to the surface of the cells and are removed by the monocyte macrophage phagocytic system in the spleen

< 30,000/mL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
82
Q

Secondary ITP

A

or acquired ITP can occur due to infectious, inflammatory, neoplastic, or toxic processes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
83
Q

Primary ITP

A

diagnosed based on exclusion of other causes; in cases of acquired ITP, the underlying cause must be determined in order for treatment to be effective.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
84
Q

Blood smear platelet count

A

Each 100× field should contain 8–15 platelets, with each platelet visualized representing approximately 15 000/μL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
85
Q

Why is vincristine used for ITP treatment?

A

– vinca alkaloid and immunomodulating antitubular agent
– works by inducing release of platelets from megakaryocytes through premature fragmentation and by impairing the consumption of platelets by macrophages

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
86
Q

Veterinary blood products and components that contain platelets

A

fresh whole blood,
fresh platelet concentrate,
cryopreserved platelets,
lyophilized platelets, and
platelet‐rich plasma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
87
Q

Effusions

A

Pure Transudate: < 2.5g/dl
–PLE, PLN, portal hypertension, PSS
Modified transudate: 2.5-5.0 g/dl
–blood, neoplasia, CHF, Liver dz
Exudate: > 5 g/dl
–purulent, pyothorax

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
88
Q

Lactate forms found in the body

where is it metabolized?

2 types

A

D-Lactate = non-physiological (short bowel syndrome)
L-Lactate = main form of lactate in body
–produced in skeletal muscle, brain tissue, adipose tissue and circulating blood cells
–Metabolized in Liver (60%) and Kidney (30%)
– <3 uses lactate for ATP production

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
89
Q

Normal energy Metabolism

A

Glucose → glycolysis → pyruvate + 2 moles of ATP per mole of glucose
→ pyruvate enters mitochondria → 36 moles of ATP/glucose mole

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
90
Q

Energy metabolism under Anaerobic conditions

A

Abnormal anaerobic conditions → inadequate O2 supple
–glycolysis rate too high for mitochondria metabolism to keep up → accumulation of pyruvate and NADH = becomes main source of energy production for ATP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
91
Q

Glycolysis role in producing lactate

A

Glycolysis → glucose = pyruvate → lactate → NADH
–Lactate dehydrogenase activity ↑ = ↑ lactate to pyruvate ratio

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
92
Q

Measured Lactate

A

– Indirect measure of tissue O2 balance
Liver cannot eliminate amount of lactate produced by hypoxic tissue = level of lactate we measure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
93
Q

Cori Cycle

A

Reverses lactate metabolism when aerobic metabolism restored

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
94
Q

Type A Lactate examples

A

Oxygen Related
↑ O2 demand:
–exercise, shivering, tremors, sz
↓ O2 availability:
– shock, LV failure, CPA, Pulmonary dz
↓ Arterial O2 content:
Acute Anemia, hypoxemia, CO poisoning

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
95
Q

Type B Lactate

A

Not directly O2 related → metabolic
B1= Systemic dz → inflammatory process affecting cells ability to proccess O2
B2 = Drugs or Toxins → medication related to metabolic hyperlactemia, acetaminophen, corticosteriods, Catecholamines
B3 = Hereditary dz → congenital hyperlacemia (GSP), enzyme deficiencies, pyruvate dehydrogenase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
96
Q

FFP

A

– plasma that has been separated from red blood cells and frozen within 8 hours
– contains all of the coagulation factors, anticoagulants, alpha macroglobulins, albumin, fibrinogen, and fibronectin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
97
Q

Frozen Plasma

A

fresh plasma is frozen for more than a year (frozen plasma) or kept at room temperature for more than 8 hours, it loses its labile clotting factors (factors V and VIII).
– Frozen plasma contains clotting factors II, VII, IX, X and plasma proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
98
Q

Cryoprecip

A

created by slowly thawing and centrifuging FFP
– centrifuged supernatant is discarded, and the remaining solution (CRYO) contains vWF, factor VIII, fibrinogen, and fibronectin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
99
Q

Cryopoor Plasma (CPP)

A

CPP is the supernatant removed after FFP has been centrifuged
– contains albumin, globulin, antithrombin, protein C, protein S, and factors II, VII, IX, and X
– albumin concentration and COP were highest in CPP compared with CRYO or FFP
– CPP is a reasonable alternative to FFP for albumin replacement and oncotic support

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
100
Q

Albumin

6 important functions

A

Albumin makes up 70%–80% of COP within the body
– plays an important role in wound healing; as an antioxidant, free-radical scavenger, and transport agent; and in preserving normal platelet function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
101
Q

Causes of hypoAlb

A

protein-losing nephropathy, protein-losing enteropathy, end-stage liver failure, malnutrition, and systemic inflammatory states

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
102
Q

Alb deficit equation

A

albumin deficit (g) = 10 × 0.3 × BW (kg) × (desired albumin – patient albumin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
103
Q

HSA administration dose

A

2ml/kg 25% HSA is administered IV over 2 hours followed by 0.1 to 0.2 ml/kg/hr for 10 hours, for a total dose of up to 2 g/kg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
104
Q

Marked leukocytosis and polycythemia with hypoglycemia

A

because of increased cell utilization of glucose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
105
Q

Pathologic hemolysis

A

– occurs when the rate of destruction is increased, and the life span of RBCs is shortened

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
106
Q

Hemolytic anemia (HA)

A

results when regeneration of RBCs from precursor cells is inadequate to replenish the destroyed cells
– caused by several immunologically and nonimmunologically mediated mechanisms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
107
Q

9

Causes of Hemolysis

A
  1. Fragmentation hemolysis
  2. Toxicant-induced hemolysis
  3. Foodstuffs and additives
  4. Drugs
  5. Chemicals
  6. Immune-mediated hemolysis
  7. Heritable hemolysis
  8. Infection-related hemolysis
  9. Miscellaneous
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
108
Q

Fragmentation hemolysis

How does it occur?
What type of cell is typically seen?

A

mechanical process, most commonly the result of shearing of the RBC membrane in the small vessels (microangiopathic hemolysis) or from altered rheologic forces
– Because shearing occurs inside the vascular space, hemoglobinemia and hemoglobinuria commonly result
– observation of schistocytosis on a peripheral blood smear provides supportive evidence of fragmentation; keratocytes and acanthocytes also are seen
– Assays of coagulation to check for DIC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
109
Q

Toxicant-induced hemolysis

A

– often related to oxidative injury
– Oxidation of hemoglobin iron results in the formation of methemoglobin, which, although unable to bind oxygen, does not shorten RBC life span
– Cats are more susceptible to chemical oxidant injury than dogs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
110
Q

What causes Heinz-bodies?

A

Oxidation of hemoglobin causes Heinz body formation
– ultimately resulting in RBC removal

Propofol use in cats

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
111
Q

Substances that can cause toxicant-induced hemolysis

5 examples

A
  1. Onion/Garlic
  2. Propylene glycol → propofol
  3. Zinc/Copper
  4. Skunk Musk
  5. Acetaminophen
  6. Benzocaine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
112
Q

Heritable hemolysis

A

– relatively uncommon
– all hereditary erythrocyte defects lead to HA
– Osmotic fragility, Phosphofructokinase deficiency, Pyruvate kinase deficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
113
Q

Infection-related hemolysis

A

result of direct cell damage, through initiation of an immunologically mediated response to infection, or both
– Systemic infections also can lead to microangiopathic hemolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
114
Q

Infection of red blood cells causes in US:

A
  1. hemotropic Mycoplasma spp.
  2. protozoan parasites → Cytauxzoon felis and Babesia spp
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
115
Q

Mycoplasma haemofelis

A

causative agent of feline infectious anemia
– Presumably transmitted by fleas, the resulting hemolysis is variable in severity, cyclic in nature, and often Coombs positive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
116
Q

Babesia most likely to cause HA in the United States

A

*B. gibsoni *
any breed can be infected, but infection in North America is most common in pit bull terriers.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
117
Q

Cytauxzoon felis

transmitted by
CS seen

A

causes a tick-transmitted infection endemic to the southeastern, midwestern, and mid-Atlantic regions of the United States
– Cats typically become sick in the warm weather months with an acute febrile illness often accompanied by icterus and pancytopenia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
118
Q

Systemic infections that may cause HA

A

– hemolysis may be due to hemotropic mycoplasmosis
– Feline leukemia
– feline immunodeficiency virus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
119
Q

Immune-mediated hemolysis

secondary vs primary

A

– destruction of RBCs is mediated by antibody or complement-triggered events
– i.e., secondary IMHA
→ infection, drugs, cancer, procedure
– occurs more commonly in dogs than cats (rare) → cocker spaniels overrepresented
primary IMHA is idiopathetic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
120
Q

7

Drugs that might trigger Secondary IMHA

A
  1. acetaminophen,
  2. cephalosporins,
  3. NSAIDs,
  4. penicillins,
  5. phenylbutazone,
  6. tetracyclines,
  7. trimethoprim‐sulfa
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
121
Q

What is the most common form of IMHA?

A

immunoglobulin-mediated type II hypersensitivity reaction causing extravascular hemolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
122
Q

3

IMHA autoantibodies invovled

A

IgG, IgM, and IgA
– produced against the animal’s own red blood cell membrane antigens regardless of the age or health of the cells
– in normal scenarios, these autoantibodies regulated by suppresor T cells
– animals with IMHA have poor T cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
123
Q

Microangiopathic hemolytic anemia

what do they result in?

A

condition in which RBCs are physically damaged during circulation due to vessel occlusion, abnormal vascular morphology, or fibrin shearing.
– Ex: splenic torsion, HWD, DIC, IVCs, hemangiosarcoma

result in Schitocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
124
Q

5

Complete blood count findings in IMHA

A
  1. regenerative anemia,
  2. leukocytosis with left shift,
  3. lymphocytosis,
  4. thrombocytopenia,
  5. elevated reticulocyte percentage
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
125
Q

Agglutination

A

– can be seen grossly and microscopically but must be differentiated from rouleaux formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
126
Q

How to differentiate between Agglutination and Rouleaux?

A

Rouleaux disperses with saline washing
True agglutination does not

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
127
Q

Treatment for IMHA: Immune suppression

A

Glucocorticoids mainstay of treatment for IMHA
– positive response may still take 3-5 days
– adjunctive immunosuppressive drugs include azathioprine and the less myelotoxic/hepatotoxic but similarly acting agent mycophenolate mofetil
– cyclosporine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
128
Q

Treatment for IMHA: supportive care

A

provision of adequate oxygen-carrying capacity via transfusion of RBCs
– need for transfusion based on clinical signs
– however reaching a certain level of anemia despite CS can still warrant transfusion due to likely hypoxia (< 12%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
129
Q

Anti-thrombotics for IMHA

A

– dogs with IMHA commonly euthanized due to complications from IMHA such as PTE or DIC
– anticoagulants = rivaroxiban, UF heparin
– antiplatelet therapy = clopidogrel, aspirin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
130
Q

Other possible complications with IMHA

x3

A

– Gastric ulceration and erosion
– both as a result of poor oxygenation of GI tissues and due to the use of high-dose glucocorticoids
– use of proton pump inhibitors as gastric protectants is only recommended routinely when ulcers are suspected

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
131
Q

Other causes of immune-mediated hemolytic anemia

A

transfusion reactions and
neonatal isoerythrolysis result from immunologically mediated but normal attack against RBCs.
– in dogs subsequent transfusions may result in hemolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
132
Q

Feline neonatal isoerythrolysis

A

Type A or type AB kittens born to type B queens can develop hemolytic anemia after absorption of alloantibodies via colostrum.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
133
Q

Hemophagocytic histiocytic sarcoma syndromes

Clin path findings

A

– severe regen anemia with thrombocytopenia
– result in a rapidly progressive severe extravascular HA that can be confused with IMHA
– Despite HA, the spherocytosis or autoagglutination typical of IMHA is absent and affected dogs are Coombs negative
– hyperbilirubinemia with hypoalbuminemia and hypocholesterolemia are commonly identified.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
134
Q

Platelet aggregation

what does it need to occur?

A

In the presence of thrombin, platelets change shape and develop pseudopods that allow them to intertwine with each other.
– platelets squeeze together to form a primary hemostatic plug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
135
Q

Thrombin Definition

A

an enzyme in blood plasma which causes the clotting of blood by converting fibrinogen to fibrin
– essential product of secondary hemostasis
– end‐result is a stable fibrin clot

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
136
Q

Thrombin actions

A

– stimulates platelets and endothelial cells to enhance clot formation

– affects the natural inhibitors of coagulation, causing consumption of antithrombin (AT) and protein C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
137
Q

Fibrinogen

what does it become and how?

A

a soluble plasma protein present in blood
– from which fibrin is produced by the action of the enzyme thrombin.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
138
Q

Fibrin

A

an insoluble protein formed from fibrinogen during the clotting of blood.
– It forms a fibrous mesh that impedes the flow of blood by keeping platelets in place

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
139
Q

Primary hemostasis definition

A

activated platelets form a platelet plug in minutes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
140
Q

Secondary hemostasis definition

what initiates it?

A

reinforcement of the frail platelet plug with fibrin strands occurs within hours
Factor VII and tissue factor (factor III) are considered the main initiator of secondary hemostasis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
141
Q

Fibrinolysis definition

A

the enzymatic breakdown of the fibrin in blood clots

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
142
Q

Primary hemostasis pathway

where does it take place?
how is a clot formed?
what actions do platelets have?

A

Takes place between the injured vessel wall and platelets.
→ results in the formation of a platelet plug at the site of a vascular injury; activated platelets, along with endothelial cells = form an unstable fibrin clot.
→ This platelet plug fulfills multiple purposes:
* provides a physical barrier to inhibit loss of blood
* provides membrane surfaces as binding sites for procoagulant enzymes that aid the formation of thrombin in secondary hemostasis.
→ In primary hemostasis, following platelet adherence, platelets undergo conformational changes and release substances that stimulate platelet aggregation.
→ Aggregated platelets constitute the primary hemostatic plug.

3 phases: 1 Initiation, 2 Extension, Stabilization

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
143
Q

Main mechanism for primary hemostasis

A

platelets

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
144
Q

Primary Hemostasis

1 Initiation

A

binding of platelets to collagen and vWF triggers platelet activation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
145
Q

Primary Hemostasis

2 Extension

A

Extension of the adhered platelet monolayer on injured vessels undergoes further activation resulting in secretion, shape change, formation of the procoagulant membrane, and integrin activation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
146
Q

Primary Hemostasis

Stabilization

A

forces generated by contraction of actin/myosin filaments in platelet further strengthen platelet-to-platelet interactions by narrowing the gap between platelets and preventing the diffusion of activators away from the platelets, hence fostering a local procoagulant microenvironment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
147
Q

Secondary hemostasis pathway

A

→ formation of fibrin in and around the primary plug, stabilization of the platelet clot through the generation of thrombin (factor II), and activation of the fibrinolytic system.
→ known as the coagulation cascade.
two pathways for the activation of the coagulation cascade: intrinsic and extrinsic.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
148
Q

main initiator of secondary hemostasis

A

Factor VII and tissue factor (TF; Factor III)
– Factor VII synthesized in liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
149
Q

Intrinsic pathway

What does it work on?
What factors does it involve?

A

surface activated, operating strictly with components present in the blood
Factors XII, XI, IX, VIII

12-11 = 1, 9-8 = 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
150
Q

Extrinsic pathway

What does it work on?
What factors does it involve?

A

requires tissue factor for activation
Factors: III (TF), VII

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
151
Q

Where are clotting factors produced?

A

All coagulation factors are produced in the liver, with the exception of factor VIII

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
152
Q

What is factor IV?

A

Calcium
– required for most reactions and is the reason why calcium chelators such as citrate and ethylenediaminetetra‐acetic acid (EDTA) are used for blood collection
– Binding agent for Vit K dependent factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
153
Q

Which factors require Vit K?

A

Factors: II, VII, IX, X

2+7 = 9 then 10

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
154
Q

What initiates the coag cascade?

A

exposure of tissue factor (TF) which is also known as factor III

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
155
Q

Coag Cascade pathway

A

TF is exposed from vascular endothelial cell damaged but also contributed by activated monocytes and inflammatory mediators.
– After being exposed, TF binds to factor VII → forms a thrombin complex that initiates the extrinsic cascade.
→ small amount of thrombin produced activates clotting factor XI to factor XIa,
→ which activates factors V, VIII, and XIII.
– Through processes, thrombin formation is maintained.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
156
Q

Fibrinolytic system

A

consists of plasminogen and many other substances that convert plasminogen to its active form, plasmin

157
Q

Plasmin

A

Plasmin is ultimately responsible for dissolution of the fibrin clot.
– exists in circulation as the proenzyme plasminogen.
– Plasmin’s cleavage of fibrin releases fibrin degradation products (FDPs) and D‐dimers that are used to monitor fibrinolytic activity and are clinical markers for DIC
– converted from Plasminogen + t-PA/u-PA

158
Q

Plasminogen

A

– produced in Liver
– present in tissues in kidney and brain
– important role in Fibrinolysis
Plasminogen is activated and convert to plasmin primarily by tissue‐type plasminogen activator (t‐PA) and urokinase‐type plasminogen activator (u‐PA)

159
Q

tissue‐type plasminogen activator (t‐PA)

A

produced by endothelial cells and is essential to intravascular fibrinolysis
– used as Thrombolytic agent, second generation agent

160
Q

α2 anti-plasmin

A

inhibits plasmin and therefore fibrinolysis
– produced by liver
– binds plasminogen and interferes with the fibrin–plasminogen interaction because both involve the same lysine binding site

161
Q

plasminogen activator inhibitor 1 (PAI-1)

A

– important inhibitor of fibrinolysis
– main source for PAI-1 is platelets

162
Q

urokinase

A

– urinary-type plasminogen activator
– released upon activation of injury with t-PA
– converts plasminogen to plasmin
– also commercially made for treatments as Thrombolytic agent, first generation

163
Q

Thrombin-activatable fibrinolysis inhibitor (TAFI)

A

TAFI,
– produced by the liver
– activated by the thrombin/thrombomodulin complex and by plasmin
– removes the C-terminal lysine residues and therefore inhibits fibrinolysis.

164
Q

Inhibitors of Fibrinolysis

x3

A

– A2- antiplasmin
– plasminogen activator inhibitor 1 (PAI-1)
– Thrombin-activatable fibrinolysis inhibitor (TAFI)

165
Q

Thrombolytic agents

Streptokinase

A

– Streptokinase is considered a first-generation thrombolytic
– readily binds circulating plasminogen, potentially inducing a systemic lytic state
– Streptokinase has a longer half-life compared to t-PA
– extracellular protein produced by streptococci that binds plasminogen in a 1:1 complex promoting the conversion to plasmin

166
Q

Indications for thrombolytic agents

A

–acute PTE
– deep vein thrombosis (DVT), acute myocardial infarction (AMI), and acute ischemic stroke (AIS) in people

167
Q

Where is Fibrin degradation?

A

products are ultimately removed from circulation by the liver

168
Q

Relationship between Thrombin and plasmin?

A

– thrombin affects numerous phases of hemostasis, and plasmin opposes these actions.
– Thrombin “coagulates” and plasmin then “derogates.”

169
Q

immunothrombosis

A

– active initiator of thrombosis through the activation of neutrophils, monocytes, and dendritic cells to propagate clot formation and activate platelets
– can become dysregulated in diseases resulting in excessive clot formation or consumptive coagulopathy

170
Q

Effect of thrombin on platelets

A
  1. release of platelet granule contents,
  2. irreversible platelet aggregation,
  3. platelet consumption (which can result in thrombocytopenia)
171
Q

How is Plasmin activated?

A

Thrombin activates its opposing enzyme plasmin through activation of plasminogen

172
Q

Buccal Mucosal Bleeding Time

what does it assess?
what is normal for dog vs cat?
what does an abnormal result reflect?

A

used to assess primary hemostasis and platelet function
– normal time for a dog to form a visible clot in the incision is < 4 minutes.
– normal time for a cat to form a visible clot in the incision is < 2–2.5 minutes
– prolonged BMBT could reflect thrombocytopenia, von Willebrand’s disease, or thrombocytopathy

173
Q

Activated Clotting Time

What does this assess? which pathways and how?
What does an abnormal result mean?

A

– used to assess secondary hemostasis and specifically screen for abnormalities in the intrinsic and common pathways by measuring the time for a fibrin clot to form
– A prolonged ACT can be due to deficiencies in intrinsic or common pathway factors or severe thrombocytopenia (e.g. < 10 000/μL)

174
Q

Prothrombin Time

A

used to assess secondary hemostasis and specifically measures the extrinsic and common pathway factors.
– does not require a normal platelet count.
– Only a significantly prolonged PT is a relevant clinical finding → require elevations of 1.25–1.5 times the high end of normal before considering a PT truly prolonged.

175
Q

4

A prolonged PT but normal activated partial thromboplastin time (aPTT) may occur with

A
  1. factor VII deficiency from warfarin therapy,
  2. inherited factor deficiency,
  3. early vitamin K deficiency or antagonism,
  4. DIC.
176
Q

Which coagulation test becomes prolonged first with anticoag-based rodenticide toxicity?

A

due to short half‐life of factor VII (~6 hours in the dog), the PT is the first test to become elevated in patients with anticoagulant‐based rodenticide toxicity

177
Q

What may cause spurious prologed PT results?

A

Overdilution of plasma with citrate will spuriously prolong PT (and aPTT) test results.
– may also occur in severely anemic animals

178
Q

Activated Partial Thromboplastin Time (aPTT)

A

– used to assess secondary hemostasis and specifically measures the intrinsic and common pathway factors
– similar to but more specific than the ACT test.
– does not require a normal platelet count
– elevations of 1.25–1.5 times the high end of normal before considering an aPTT truly prolonged

179
Q

A prolonged aPTT with a normal PT suggests:

A

defect in the intrinsic pathway (e.g. factors XII, XI, IX, VIII)

180
Q

prolonged PT and aPTT together can occur with:

A

multiple factor deficiencies; affecting both factor VII, extrinsic, intrinsic or common pathway factor deficiencies.
– including:
* inherited factor X deficiency or
* acquired defects such as vitamin K deficiency or antagonism,
* DIC
* liver failure
* hypofibrinogenemia

181
Q

What drug will cause aPTT to be prolonged without affecting PT?

A

Treatment with unfractionated heparin will prolong the aPTT without affecting the PT

182
Q

What diseases will cause prolonged aPTT without affecting PT in dogs?

A
  1. Hemophilia A (factor VIII deficiency)
  2. Hemophilia B (factor IX deficiency)
183
Q

Protein Induced by Vitamin K Antagonism Test (PIVKA)

A

rare test used to assess vitamin K‐dependent coagulation factors (i.e. II, VII, IX, X)
– factors are produced in the liver initially as non‐functional precursors and then become active in the presence of vitamin K
– w/o Vit K there is an abundance of inactive precursors that can be measured

184
Q

Thromboelastography (TEG) and Thromboelastometry (ROTEM) tests

A

used to provide global assessment of the dynamics of clot development, stabilization, and dissolution
– these tests evaluate clot initiation, amplification, propagation, and fibrinolysis, including the interaction of platelets with proteins of the coagulation cascade

185
Q

What does each value mean?

A
  1. Reaction time (R): The time to onset of fibrin formation (or when the curve deviates by more than 2 mm from midline).
  2. K: The time it takes for the curve to deviate 20 mm from the centerline (rate of fibrin formation).
  3. α: The angle between the time point K and the centerline (rate of fibrin formation).
  4. Maximum amplitude (MA): Strength of the clot.
186
Q

Fibrin Degradation Product (FDP)

A

occasionally used in dogs and cats to assess a patient’s fibrinolytic activity
– FDP, specifically fragment D and E, are end‐products of cleavages from fibrinogen and fibrin
– rise in many conditions, including DIC, thrombosis, hemorrhage, or any condition causing decreased clearance of FDPs by the liver and monocyte‐macrophage system (e.g. liver failure)

187
Q

D‐Dimer Test

A

used in dogs and cats to assess fibrinolytic activity
– specific plasmin‐mediated breakdown product of cross‐linked fibrin.
– more specific than FDP
– increases whenever there is activation of thrombin to form cross‐linked fibrin and fibrinolysis.
– Ex: thrombosis, DIC, surgical wound healing, neoplasia, hemorrhagic effusions, and fibrinolysis

188
Q

Disseminated Intravascular Coagulation definition

A

– acquired syndrome characterized by intravascular activation of coagulation leading to generalized coagulopathy.
– can originate from damage to the microvasculature which, if sufficiently severe, can lead to thrombosis and organ dysfunction.
– endothelial damage, platelet activation, or a release of tissue procoagulants

189
Q

DIC Pathophysiology

A

initial activation from proinflammatory cytokines → intravascular fibrin formation, microvascular thrombi and organ dysfunction, consumptive intravascular coagulopathy and thrombocytopenia
→ ultimately widespread hemorrhage

190
Q

10

Disease processes that can lead to DIC

A
  1. sepsis, shock,
  2. immune‐mediated disease,
  3. envenomation,
  4. burns,
  5. heat stroke,
  6. trauma,
  7. pancreatitis,
  8. malignancy,
  9. severe hepatic failure,
  10. major surgery

typically acute

191
Q

What can cause “chronic DIC”?

A

hemangiosarcoma in dogs

192
Q

DIC diagnosis

x5 clin path findings

A

no single test for diagnosing DIC and several hematological findings must be used in conjunction to support a presumptive diagnosis
1. regenerative hemolytic anemia,
1. hemoglobinemia,
1. red cell fragmentation (schistocytosis),
1. neutrophilia with a left shift,
1. and thrombocytopenia

193
Q

7

Other laboratory abnormalities associated with DIC:

A
  1. decreased fibrinogen,
  2. prolonged thrombin time,
  3. prolonged PT,
  4. prolongation of aPTT,
  5. production of FDPs,
  6. elevated D‐dimers,
  7. decreased concentrations of AT
194
Q

DIC treatment

x4

A
  1. fresh frozen plasma
  2. cryoprecipitate therapy for fibrinogen supplementation
  3. Unfractionated or low molecular weight heparins can also be considered in patients that are not actively bleeding
  4. Platelet transfusion for thrombocytopenia and factor IIa administration
195
Q

Acquired Coagulopathy causes

A

caused by production defect:
liver failure,
vitamin K deficiency as an activation defect

196
Q

Acquired Coagulopathy: Liver Failure

A

liver is the primary site of coagulation factor synthesis
→ diseases that cause liver insufficiency or failure,
→ acute liver failure, portosystemic shunt, or cholestasis, will subsequently cause factor deficiency or dysfunction

197
Q

Acquired Coagulopathy: Vit K deficincies

A

Vitamin K is essential to coagulation and liver disease is associated with vitamin K deficiency due to impaired intrahepatic recycling
– conditions such as infiltrative bowel disease, biliary obstruction, or pancreatic insufficiency cause decreased vitamin K absorption in the intestinal tract.
rodenticide toxicity induces severe coagulopathy caused by vitamin K deficiency.

198
Q

Von Willebrand’s Disease

A

most common inherited bleeding disorder of dogs
– result of a deficiency in von Willebrand’s factor (vWF) a large, multimeric glycoprotein found in plasma, platelet granules, endothelial cells, and subendothelial connective tissue.

199
Q

Where is vWF made?

A

synthesized by the vascular endothelium and megakaryocytes, and is necessary for normal platelet function.
– vWF needed for platelet adhesion

200
Q

vWF mechanisms

3

A
  1. mediates platelet adhesion to exposed endothelium after vascular injury,
  2. promotes platelet aggregation under high shear conditions,
  3. serves as a carrier for coagulation factor VIII.
201
Q

vWF deficiency effects

A

– experience a range of hemorrhagic states ranging from mild bleeding to life‐threatening hemorrhage following injury or surgery
– since vWD is a platelet function defect, all coagulation tests, including the platelet count, will be normal except those that assess primary hemostasis and require functional platelets, such as the BMBT.

202
Q

most common form of vWD

A

type 1 in which vWF levels are notably decreased
– autosomal dominant and is common in certain breeds such as the doberman
– Dogs are usually non‐clinical until a surgical or trauma event, in which they may experience prolonged bleeding

203
Q

What may exacerbate bleeding tendencies in dogs with vWD?

A

Hypothyroidism

204
Q

3 examples

vWF deficiency treatment

which one is preferred?

A

– In emergencies: transfusions with fresh whole blood or fresh frozen plasma may stabilize a bleeding patient with vWD
cryoprecipitate contains factor VIII, vWF, fibrinogen, and fibronectin, is preferred for the management of patients with vWD
– desmopressin (DDAVP) is a synthetic vasopressin analogue that through the V2 receptor results in the release of body vWF stores

205
Q

Epistaxis

common causes #10

A

hemorrhage originating from the nose can result from intranasal or extranasal systemic causes
Common causes of epistaxis include:
1. coagulopathy,
1. platelet disorder such as ITP,
1. systemic hypertension,
1. nasal tumor,
1. nasal foreign body,
1. nasal trauma,
1. oronasal fistula,
1. immune‐mediated rhinitis,
1. fungal infection of the nose,
1. DIC.

206
Q

Acute Traumatic Coagulopathy

A

occurs in patients with severe trauma, known as acute traumatic coagulopathy (ATC)
– condition of hypocoagulation and hyperfibrinolysis that occurs in the absence of clotting factor consumption

207
Q

Acute Traumatic Coagulopathy

ATC: Pathophysiology

What is the key component?

A

– Trauma induces endothelial injury and hypoperfusion, leading to fibrin formation.
– Enhanced fibrinolysis then occurs, leading to a hypocoagulable state
– consumption of fibrinogen and fibrinolysis by the action of plasmin is a key component of ATC

208
Q

Acute Traumatic Coagulopathy

ATC coagulopathy tests

A

expected to have a prolonged PT, aPTT,
and decreased maximum amplitude (MA) on thromboelastography (TEG)

209
Q

Lymphatic System Disorders

A

divided into those of internal organs and those of the peripheral lymphatics
– lymphangitis and lymphadenitis and are typically secondary to local inflammation, involving the skin, mucous membranes, or the subcutaneous tissues.

210
Q

Lymphangitis causes and effects:

A

result from bacterial, fungal, inflammatory, or adjacent neoplasia
– lymphatics become affected and potentially occluded as they drain inflammatory by‐products from the tissues.
– Pyrexia, anorexia, and leukocytosis may be present with acute lymphangitis

211
Q

Lymphadenitis

A

–lymph nodes, micro‐organisms are phagocytized, destroyed, or inactivated, which may cause the node to become enlarged or obstructed.

212
Q

Lymphedema

A

result of accumulation of fluid in the interstitial space secondary to abnormal lymphatic drainage.
– categorized as either primary or secondary

213
Q

Primary lymphedema

A

capillary filtration exceeds resorption capacity; the protein‐rich fluid causes a high osmotic gradient and exacerbates fluid accumulation.
– refers to an abnormality of the lymphatic vessels or lymph node

214
Q

Secondary lymphedema

A

– refers to conditions caused by a disease in the lymphatic vessel or lymph node that actually began in a different tissue.
– more common than primary lymphedema, occurring as a result of neoplasia, trauma, parasites, or infection.

215
Q

Hypercoagulability or thrombophilia definition

A

propensity for inappropriate thrombus formation
– balance has been tipped in favor of coagulation, which may arise due to a variety of derangements
–result of inherited or acquired causes

216
Q

Mechanisms of thrombophilia

Glycocalyx review

A

endothelial barrier is composed of vascular endothelial cells (ECs) and a thin carbohydrate-rich luminal glycocalyx that localizes many key anticoagulant elements.

217
Q

Glycocalyx is composed of

x3

A
  1. network of negatively charged glycosaminoglycans (GAGs)
  2. proteoglycans
  3. glycoproteins.
218
Q

Proteoglycans:

A

– facilitates the binding of antithrombin (AT)
– 50-90% made up of Heparan sulfate
increased thrombin inhibition

219
Q

Other mechanisms of glycocalyx

A

serves as a mechanoreceptor, sensing altered blood flow and releasing nitric oxide (NO) during conditions of increased shear stress to maintain appropriate organ perfusion.

220
Q

Nitric Oxide role in the inflammatory response

x2

A
  1. leukocyte adhesion to the endothelium
  2. inhibition of platelet aggregation.
221
Q

Glycocalyx mechanisms with inflammation

A

inflammation decreased synthesis of the GAGs that comprise the glycocalyx,
→ decreasing the function of the anticoagulants that rely on the glycocalyx (e.g., TM and protein C, TFPI)
→ glycocalyx also buffers ECs by preventing the binding of inflammatory cytokines to cell surface receptors.

222
Q

5

Endothelial Cells can be activated by

A
  1. TNF-α,
  2. bradykinin,
  3. thrombin,
  4. histamine,
  5. vascular endothelial growth factor
223
Q

Endothelial disruption exposes

A

procoagulant substances such as tissue factor [(TF) fIII] to the circulating blood.

224
Q

coagulation in vivo is initiated through

A

interaction of Tissue Factor (TF) fIII with activated factor VII (fVIIa)

Extrinsic pathway

225
Q

Role of platelets as a pro-coagulant element

A

– serve as a source of procoagulant membrane.
–platelets undergo a shape change and shuffle negatively charged phospholipids
– These provide the catalytic surface essential for the tenase and prothrombinase complexes for the propagation phase of clot formation

226
Q

Reltionship between vWF and Endothelial Cells

A

when ECs become injured, they release ultra-large multimers of vWF (UL-vWF) from the Weibel-Palade bodies
– needed for platelets to attach to subendothelium collagen

227
Q

Microparticles (MPs)

A

– circulating small vesicles (membrane blebs) released from activated or apoptotic cells
– derived from platelets, ECs, leukocytes, erythrocytes, and neoplastic cells.
– can express TF on their surface,

228
Q

neutrophil extracellular traps (NETs)

A

released from activated neutrophils
– consist of nuclear contents, including DNA, histones, and some extranuclear proteins
– their role is to immobilization and sequestration of microbial elements as a response to septicemia;
– also released by PAMPs interaction
– can be procoagulant

229
Q

Endogenous anticoagulants role

x3 examples

A

essential to localizing coagulation to the site of vascular insult
– simultaneous activation of anticoagulant factors, even during clot propagation, helps to prevent a procoagulant state or the dissemination of coagulation
– examples: Antithrombin, protein C, and Tissue factor pathway inhibitor (TFPI)

230
Q

Antithrombin (AT)

A

– primarily acts to inhibit thrombin and factor Xa
– typically decreased in systemic inflammation or critical illness via 3 pathways:
1. consumption (due to thrombin generation),
1. decreased production (negative acute phase protein), or
1. degradation by NE.

231
Q

protein C system

A

important inhibitor of factors Va and VIIIa
– less functional during systemic inflammation due to decreased hepatic synthesis of proteins C and S

232
Q

Tissue factor pathway inhibitor (TFPI)

A

released primarily from ECs and acts to inhibit fVIIa-TF complexes and factor Xa (fXa);
– or all components of the TF- or extrinsic pathway
– Other sources of TFPI include platelets, mononuclear cells, vascular smooth muscle and cardiac myocytes, fibroblasts, and megakaryocytes

233
Q

Fibrinolysis

A

– final protective step to prevent vascular occlusion → fibrin clot must be dissolved to allow the reestablishment of blood flow
– Thrombi remaining in the macro- or microvasculature can impair organ perfusion and oxygen delivery, and may provide a second insult that leads to MODS

234
Q

Basic Diagnostics for Hypercoagulability

A

– Prolongations of aPTT/PT and decreased platelet count
– due to consumption of platelets and coagulation factors following unregulated thrombin generation

235
Q

Platelet count changes with consumptive coagulopathy

A

drop in circulating platelet count accompanied by a ≥20% prolongation in baseline aPTT in an at-risk patient should raise concern of a consumptive coagulopathy

236
Q

Advanced Diagnostics for hypercoagulopathy

A
  1. rise in procoagulant elements (e.g., MPs, fV or VIII activities, or fibrinogen),
  2. decrease in endogenous anticoagulants (e.g., AT, protein S and C, or TFPI),
  3. decrease in fibrinolysis (e.g., decreased tPA; increased α2-antiplasmin, PAI-1, TAFI).
237
Q

SIRS

coagulopathy associated with systemic inflammation

A

involves:
1. increased expression of TF,
1. activation of ECs and disruption of the glycocalyx,
1. impairment of anticoagulant systems,
1. reduction of fibrinolysis.

238
Q

SIRS

glycocalyx shedding and EC activation in the face of inflammation:

A

– leads to compromised production of local regulators (e.g., NO)
– increased expression of procoagulant molecules (e.g., UL-vWF or TF)
– and adhesion molecules (e.g., P-selectin) with derangement of anticoagulant defenses.

239
Q

SIRS

thrombomodulin [TM] dysfunction from inflammation

A

may be damaged by multiple mechanisms (leading to decreased activation of protein C),

240
Q

SIRS

Antithrombin dysfunction from inflammation

A

– Antithrombin is less effective due to both decreased concentrations and impaired interactions with an endothelium that has been layered of GAGs.

241
Q

Potential Lab findings in dogs with sepsis

A

– significantly prolonged aPTT and/or PT, along with higher FDP and D-dimer
– lower protein C and AT activities → consumptive
– TAFI is increased

242
Q

Hypercoagulopathy

thrombophilia associated with PLN

A

– increases in fVIII activity and fibrinogen concentration
– Platelets are hyperaggregable and exhibit increased markers of activation
– AT activity was lower in PLN

243
Q

Hypercoagulability with IMHA

A

low AT activity, elevated fibrin[ogen] degradation product [FDP], and D-dimer, and markedly elevated fibrinogen concentration
– TEGs increased MA (clot strength)
– increased concentrations of circulating cfDNA due to NET formation from neutrophil response to hypoxia/inflammation/free heme exposed
– Circulating TF contributes to procoagulant state

244
Q

Hypercortisolemia (hyperadrenocorticism) risk of hypercoagulopathy

A

– no consistent cause or definable procoagulant state has been identified
– pts can present with thrombic conditions
– study found increased activities of factors V, XI, AT, and elevated plasminogen
TEG changes consistent with procoagulant state

245
Q

Cardiomyopathies risk for hypercoagulopathy

A

– Arterial thromboembolism (ATE) in cats
– Left atrial (LA) and LA appendage enlargement associated withprocoagulant phenotypes; increased TF and vWF
– 50% of cardiomyopathic cats with spontaneous echocardiographic contrast (or “smoke”) with or without a LA thrombus
– cats with thyrotoxic cardiomyopathy, platelets were less responsive to ADP and more responsive to collagen for aggregation

246
Q

Coagulopathies with Neoplasia

3 examples

A

– dogs with hemangiosarcoma, mammary carcinoma, and adenocarcinoma of the lung
TF has been identified on malignant cells and in the tumor vasculature, and these cells have the ability to shed TF-bearing MPs
– distant metastasis commonly have higher fibrinogen and D-dimer levels than locally invasive or noninvasive disease
– canine patients with carcinomas, thrombocytosis and hyperfibrinogenemia were more common
– dogs with untreated mammary carcinoma included hyperfibrinogenemia, elevated fV, and decreased fVIII activities

247
Q

2 types and their examples

Antithrombotic therapy definition

A

consist of drugs that inhibit platelet function (e.g., aspirin or clopidogrel) or drugs that facilitate the inhibition of thrombin (e.g., unfractionated heparin (UFH) or low molecular weight heparin [LMWH])

248
Q

Hypercoagulopathy definiton

A

two or more of the following:
1. coagulation factor excess (i.e., high fibrinogen concentration or factor VIII coagulant activity),
1. inhibitor deficiency (i.e., low antithrombin activity),
1. thrombin generation (i.e., high thrombin-antithrombin complex and d-dimer concentrations)

249
Q

complications following thrombolysis

A

hyperkalemia, acute kidney injury, clinical bleeding, and coagulation abnormalities.

250
Q

commonly prescribed antiplatelet medications

A

Aspirin and clopidogrel

251
Q

Aspirin MOA

A

acts on the arachidonic acid pathway and irreversibly inhibits the cyclooxygenase pathways

252
Q

Clopidogrel MOA

A

– is a thienopyridine that selectively inhibits ADP-induced platelet aggregation but has no direct effects on arachidonic acid metabolism
– requires hepatic biotransformation to produce the active metabolite.

253
Q

Commonly used anticoagulants

A

warfarin,
unfractionated heparin (UFH),
low-molecular weight heparin (LMWH)

254
Q

unfractionated heparin (UFH)

A

– pharmacokinetics of UFH are quite variable and depend on the proportion of heparin molecules large enough to bind thrombin
– therapy must be monitored closely and titrated to effect to avoid under treatment or bleeding complications

255
Q

Target value when using UFH

A

use the aPTT, with an accepted therapeutic target range of 1.5 to 2.5 times the normal control aPTT value.

256
Q

low-molecular weight heparin (LMWH)

A

– LMWH has reduced anti-IIa activity relative to anti-Xa activity and also has better predictable pharmacokinetic properties.
– standard doses has a minimal effect on aPTT
– One potential benefits is its reduced affinity for binding to plasma proteins or cells compared with UFH, leading to a more predictable dose response relationship and longer half-life
– 100% bioavailability after subcutaneous administration

257
Q

thrombocytopenia

A

– common hematologic abnormality can be caused by:
decreased production, increased consumption, increased destruction, and sequestration.
– can be acquired or congenital

258
Q

Thrombocytopenia

Examples of Increased consumption

A
  1. Disseminated intravascular coagulation
  2. Acute/severe blood loss
  3. Platelet activation/aggregation
  4. Sepsis
  5. Thrombotic microangiopathies
  6. Massive thrombosis
259
Q

Acquired intrinsic platelet dysfunction

A
  • Platelet inhibitors
  • Uremia
  • Synthetic colloids
  • Myeloproliferative disease
  • Pit viper envenomation
  • Disseminated intravascular coagulation
  • Trauma-induced coagulopathy
260
Q

Thrombocytopenia

spontaneous hemorrhage can occur when

A

– platelet count is < 30 × 109/ml
– fatal = platelet is < 10 × 109/ml

261
Q

Thrombocytopenia

Examples of Iatrogenic causes

A
  1. Hemodialysis
  2. Postcardiopulmonary bypass
  3. Hemodilution including massive transfusion
  4. EDTA-mediated
262
Q

Thrombocytopenia

Examples of Increased destruction causes

A

Primary immune mediated thrombocytopenia
Secondary immune mediated thrombocytopenia
* Anaplasmosis
* Babesiosis
* Ehrlichiosis
* Neoplasia
* RMSF
* Dirofilariasis
* Vaccination
* Drug reaction

263
Q

Thrombocytopenia

Examples of Decreased production causes

A
  • Bone marrow disease
  • Chemotherapy/Radiation
  • Immune Mediated
264
Q

Thrombocytopenia

Examples of Increased sequestration causes

A
  • Splenic torsion
  • SIRS
  • Hypersplenism
  • Severe hypothermia
265
Q

sepsis-mediated thrombocytopenia

A

result of:
1. increased platelet consumption due to direct microbial–platelet interactions,
1. platelet–leukocyte aggregate formation,
1. and increased platelet sequestration secondary to microvascular thrombosis.

266
Q

Which bacteria cause platelet aggregation?

A

Escherichia coli and Streptococcus can directly interact with platelets through a variety of molecular interactions leading to platelet activation and aggregation.

267
Q

Platelet interactions with neutrophils

A

Once activated, platelets interact with circulating neutrophils to form platelet-neutrophil aggregates and neutrophil extracellular traps (NETs),

268
Q

Uremia-associated platelet dysfunction

A

– due to defects in platelet adhesion, secretion, and aggregation
– uremia may directly alter the function of vWF producing a phenotypic resemblance of type II von Willebrand disease (vWD) in humans
– defects in vWF may manifest more profoundly in the microcirculation, where shear forces are high

269
Q

Liver disease associated thrombocytopenia and platelet dysfunction.

A

– Decreased platelet aggregation in response to collagen and arachidonic acid has previously been documented in dogs with liver disease, but its underlying mechanism is unknown

270
Q

Drug-associated platelet dysfunction: Nonsteroidal Antiinflammatory Drugs

A

Conflicting data in the literature. May exacerbate platelet dysfunction in animals with increased thrombopoiesis.

271
Q

Drug-associated platelet dysfunction: Selective phosphodiesterase (PDE) inhibitors:

A

Pimobendan: vitro antiplatelet effects seen at 1000x fold higher than clinically achievable concentration
Sildenafil: Potentiation of platelet inhibition with concurrent use of nitric oxide donors

272
Q

Drug-associated platelet dysfunction: Nitric Oxide Donors

A

Sodium nitroprusside (T)
Nitroglycerin (T)

273
Q

Drug-associated platelet dysfunction: Antithrombotics

A

Heparin
Factor X inhibitors:
Rivaroxaban
Apixaban
– synergistic inhibitions of tissue factor-mediated platelet aggregation and platelet-dependent thrombin generation occur when given with antiplatelet drugs

274
Q

Drug-associated platelet dysfunction: Antimicrobials

A

Beta-lactams: Dose- and time-dependent effects on platelet function
Cephalosporins

275
Q

Which COX enzyme do platelets express?

A

Platelets express mainly the isoform, COX-1, which is irreversibly inhibited by acetyl salicylic acid, thereby modulating the biosynthesis of thromboxane A2 (TXA2) and prostaglandin.

276
Q

platelet dysfunction secondary to hydroxyethyl starch (HES) administration

A
  1. binding of colloidal molecules on the extracellular domains of integrin αIIbβ3 or glycoprotein 1b inhibits their conformational changes and, subsequently, platelet aggregation and adhesion.
  2. Second, binding of colloidal molecules also interferes with factor VIII/vWF complex formation causing their accelerated elimination.
  3. slowly degradable HES may further exert its inhibitory effects in platelets by interfering with intracellular signaling function.
277
Q

Congenital platelet disorders

A

– commonly result from inherited mutations in one or more genes causing platelet dysfunction or hyperactivity

278
Q

Congenital von Willebrand disease

A

– is not an intrinsic platelet disorder
– deficiency or dysfunction in vWF, which is primarily produced by endothelial cells, results in abnormal platelet adhesion and aggregation in high shear environment
– Type 1 vs Type 2

279
Q

Type 1Congenital von Willebrand disease

A

– autosomal recessive disorder caused by mutations in the vWF gene
– commonly reported in Doberman Pinschers,

Tx ; Cryoprecipitate, Desmopressin

280
Q

Type 2 vWD

A

– qualitative abnormalities in vWF and is further divided into types 2A, 2B, 2M and 2N based on the mutation involved.
– can cause more severe bleeding diatheses such as spontaneous mucocutaneous bleeding

Tx : Cryoprecipitate, Desmopressin

281
Q

Type 3 vWD

A

– most severe form of vWD, has been reported in cats and select dog breeds including Chesapeake Bay Retrievers, Shetland Sheepdogs, Scottish Terriers, and Dutch Kooiker dogs.
– characterized by the complete absence of vWF, causing spontaneous mucosal bleeding and life-threatening hemorrhage following trauma or invasive procedures.

Tx : Cryoprecipitate

282
Q

Glanzmann thrombasthenia (GT)

A

– Defect in platelet receptors
– Animals with GT have prolonged buccal mucosal bleeding times, prolonged platelet closure time
– associated with a pathogenic variant in the ITAGA2B gene

283
Q

Bernard–Soulier syndrome

A

– rare disorder characterized by macrothrombocytopenia and a decrease in platelet survival.
– reported in Cocker Spaniels with a mutation or variants in the GP9 gene,

284
Q

Chediak–Higashi syndrome (CHS)

A

– autosomal recessive disease that manifests as prolonged bleeding times in the presence of normal platelet concentrations
– smoke-blue Persian cats and is classified as an intrinsic platelet storage pool defect in the platelet dense granules causing impaired platelet aggregation in response to collagen

285
Q

Procoagulant phospholipids: Canine Scott syndrome (CSS)

A

– rare intrinsic platelet disorder found in related and unrelated German Shepherd dogs (GSD)
– homozygous for a mutation in the TMEM16F gene
– Affected dogs also have decreased budding of platelet microvesicles compared with nonaffected GSD
– unpredictable and severe, ranging from prolonged epistaxis and postoperative hemorrhage to spontaneous cavitary hemorrhage

286
Q

DDAVP to reduce bleeding

A

– can be given in animals with milder hemorrhage.
– most commonly used in bleeding patients to release von Willebrand factor and factor VIII from Weibel–Palade bodies in the endothelial cells
– enhances the density of platelet surface glycoprotein receptors, thereby increasing their adhesion potential

287
Q

Endothelium mechanisms in normal hemostasis

A

– antithrombotic tendency usually predominates in order for blood to circulate as a liquid → achieved by endothelium separating the cellular and plasmatic components of circulating blood from the prothrombotic substances
– also produces several antithrombotic substances, with either antiplatelet (e.g., prostacyclin, nitric oxide) or anticoagulant (e.g., antithrombin, thrombomodulin) activity

288
Q

prothrombotic tendency

A

supports blood clot formation at the site of vessel injury, thereby preventing excessive blood loss.

289
Q

Primary hemostasis components

A

Platelet number
Platelet function
vWF

Temporary Platelet Plug

290
Q

Secondary hemostasis components

A

Clotting factors
Cofactors (e.g., calcium, vitamin K)

Coag Cascade

291
Q

A prolonged PT with normal aPTT indicates

A

an issue within the extrinsic and/or common pathways (e.g., factor VII deficiency),

292
Q

aPTT prolongation with a normal PT suggests

A

issues within the intrinsic and/or common pathways (e.g., factor VIII deficiency in hemophilia A, synthetic colloid administration).

293
Q

Vitamin K-dependent factor deficiency (factors II, VII, IX, X) will result in

A

PT prolongation in excess of aPTT

294
Q

Cats with severe thrombocytopenia

A

are more likely to have bone marrow pathology
– ITP is rare in cats

295
Q

Inherited platelet dysfunction

A

– inherited instrinsic platelet dysfunction is uncommon
– inherited extrinsic platelet dysfunction = vWF

296
Q

Platelet Factor 3 (PF3)

A

pro-coagulant activity
– converts Fibinogen to Fibrin to form permanent thrombis

297
Q

Primary hemostasis; Coagulation

pro-constriction substances

x4

A
  1. Serotonin (comes from plts)
  2. Thromboxane (TXA2) (comes from plts)
  3. Epinephrine (SANS response)
  4. Fibrinopeptide B (comes from fibrinogen)
298
Q

Acquired platelet dysfunction

A

– clopidogrel or aspirin use
– NSAIDs are unlikely to induce clinically relevant platelet dysfunction at normal therapeutic doses, but platelet dysfunction may occur in animals with NSAID toxicity

299
Q

Inherited clotting factor deficiency

A
300
Q

Acquired clotting factor dysfunction

A

– Acquired secondary hemostatic disorders are associated with a reduced number or activity of clotting factors
– Hypoperfusion and massive transfusion of citrate phosphate dextrose adenine (CPDA)-containing blood products have been associated with severe acidemia that may impair clotting factor activity
– Vitamin K absence or antagonism
– Acute hypocalcemia

301
Q

Hemostatic dysfunction with Liver dysfunction

A

– clotting factors, endogenous anticoagulants (e.g., protein C), and fibrinolytic proteins are synthesized in the liver
– Hemostatic dysfunction typically occurs with more advanced liver disease
– Hypercoagulability has also been identified in some animals with liver disease (e.g., congenital portosystemic shunts) and could lead to serious adverse effects (e.g., portal vein thrombosis)

302
Q

Hyperfibrinolysis

A

– hyperfibrinolytic tendency can be Acute traumatic coagulopathy, liver disease, neoplasia, also purported to occur in Greyhound breeds
– Dogs with more severe hemodynamic compromise, assessed by higher plasma lactate concentrations and greater volume of plasma administered, were more likely to demonstrate a hyperfibrinolytic tendency

303
Q

Antifibrinolytic drugs

A

– Aminocaproic acid and tranexamic acid
– competitively inhibiting the lysine-binding sites on plasminogen, which prevents the conversion of plasminogen to plasmin in addition to direct inhibition of plasmin action

304
Q

Hemoglobin molecule structure

A

– composed of four subunits containing an iron atom bound to a heme group.
– enables the transport of up to four oxygen molecules at a time.
– Oxygen binds to the central iron molecule in the ferrous (Fe++) form

305
Q

Hepcidin

relationship to EPO

A

– liver produces hepcidin, a hormone that decreases the concentration of iron in the plasma.
inverse relationship between erythropoiesis and hepcidin function

306
Q

Heinz bodies

A

– aggregates of denatured, precipitated Hb molecules within erythrocytes that form as Hb with oxidative damage is metabolized
– Aggregates of denatured globin and metabolized metHb clump into HzBs and continue to coalesce until visible, pale structures can be seen within the red blood cell cytoplasm
Formation of metHb is thought to be necessary for the development of HzBs

307
Q

Heinz bodies and Ghost cells

A

Numerous HzBs can disrupt the membrane sufficiently to result in “ghost” cells; these are empty red blood cells with just a cell membrane and HzB remaining and are associated with oxidation-induced intravascular hemolysis

308
Q

Heinz bodies in cats

A

– normally spleen can perform pitting functions and remove the HzBs from the erythrocyte
– However, feline spleens have an ultrastructural variation and impaired ability to catch and remove oxidized RBCs
– healthy cats can have notable Heinz bodies in circulation with no clinical symptoms

309
Q

8

Causes of Heinz bodies

A
  1. Allium plants (onions and garlic),
  2. propylene glycol,
  3. zinc,
  4. methylene blue,
  5. crude oils,
  6. naphthalene (ingredient in moth balls)
  7. repeated use of propofol in cats
  8. copper storage dz in dogs
310
Q

Thrombosis

What causes this?

A

Thrombosis is usually defined as the pathological hemostasis leading to the occlusion of blood supply and subsequent ischemia.
– Thromboxane = results in thrombosis

311
Q

Thromboxane

A

Pro-constriction substance for vasoconstriction at injury site
– comes from Platelets
– promotes platelet aggregation

312
Q

Thrombus

A

Thrombus has been defined as an aggregation of platelets and fibrin with entrapped blood cells, and a thromboembolism is the migration of a thrombus.

313
Q

5

DDAVP use as Hemostatic agent

A

– endothelial release of vWF can enhance platelet aggregation and supplement vWF deficiencies
– DDAVP is indicated for patients with hemophilia A and von Willebrand disease (vWD) type I
– may be used to stop spontaneous hemorrhage or in the perioperative period to reduce the risk of hemorrhage during a surgical procedure
– may shorten bleeding times with congenital platelet disorders, although is unpredictable and dependent on the specific disorder
– shown to support hemostasis in patients with coagulopathy caused by chronic uremia and hepatic cirrhosis
– may also be beneficial with prolonged bleeding times caused by antiplatelet drug use, such as aspirin or clopidogrel.

314
Q

Yunnan baiyao

A

– Chinese herb developed in the early 1900s as a hemostatic agent for trauma
– proposed mechanism of action is that the drug stimulates platelet activation and alpha granule release based on an in vitro experiment
– also possesses antiinflammatory properties through modulation of the lipoxygenase and cyclooxygenase pathways of arachidonic acid metabolism

315
Q

Cryoprecipitate

A

– made from fresh frozen plasma
– high concentrations of vWF, factors V and VIII, and fibrinogen, and is a good option for treating patients with hemorrhage due to vWD or hypofibrinogenemia
– is not type-specific but treated with care as transfusion product

316
Q

buccal mucosal bleeding time (BMBT)

A

– screening test that appears to be sensitive for congenital thrombocytopathias and vWD
– normal is 3 to 4 minutes in dogs, < 2 min in cats

317
Q

activated clotting time (ACT)

A

– measured on whole blood (not anticoagulated)
– assesses the intrinsic and final common pathway of the traditional coagulation cascade; however, it is less sensitive to reductions in clotting factor activity

318
Q

TEG: Reaction time

A

Clot Time
– Initial fibrin formation (to amplitude of 2 mm)

319
Q

TEG: Kinetics

A

– Clot formation time
– assess Rate of clot formation (to 20 mm amplitude)
– Fibrinogen, FXIII, platelets

320
Q

TEG: Alpha angle

A

– measured in degrees
– assess Rate of clot formation and fibrin crosslinking
– FXIII, platelets, fibrinogen

321
Q

TEG: Maximum amplitude

A

– Maximum clot firmness
–assess clot strength
– Platelets, fibrinogen

322
Q

TEG: Lysis (LY30, LY60)

A

– Clot lysis
– assess Fibrinolysis
– plasmin

323
Q
A
  1. hypocoagulable (A), prolonged CT/R and CFT/K and decreased α angle and MCF/MA.
  2. normal (B), four standard parameters are within the reference intervals defined at our center.
  3. hypercoagulable (C) shortened CT/R and CFT/K, and increased α angle and MCF/MA.
    profiles obtained by the viscoelastic tests.
324
Q
A

hyperfibrinolytic profiles
1. (A) Note that the beginning of the tracing is also in favor of hypocoagulability. Fibrinolysis occurs 18 minutes after the initiation of the test.
2. (B) Fibrinolysis occurs 27 minutes after the initiation of the test
3. (C) cat with aortic thromboembolism 10 minutes after the administration of intravenous alteplase. Fibrinolysis occurs 5 minutes after the initiation of the test with lysis indices equal to 0% and the maximum lysis equal to 100%

325
Q

Blood types

Antibodies in the body

A

an either be naturally occurring within the body or formed after sensitization to a foreign antigen
– severity of an antibody/antigen reaction depends on the titer level and affinity of the antibody in the recipient’s body
– higher the level and affinity of antibodies, the more severe the reaction

326
Q

Blood types

antibody reactions mediated by

A

immunoglobulin M (IgM) are more severe than immunoglobulin G‐mediated reactions (IgG)

327
Q

Blood types

Canine Blood Types

A

– classified using the Dog Erythrocyte Antigen (DEA) system
– currently seven recognized antigen types within the DEA system defined by the availability of international standardized antisera

328
Q

Blood types

Canine antigen sites are known as

A

– DEA 1, 3, 4, 5, 6, 7, and 8

329
Q

Blood types

DEA 1 group

A

– considered the most antigenic group.
– antigen can be classified as “weak,” “moderate” or “intermediate,” and “strong,” or negative
– vast majority of dogs lack naturally occurring alloantibodies to the DEA 1 site
– acute antigenic reaction is unlikely to occur with the patient’s first transfusion

330
Q

Blood types

mismatches always result in

A

delayed hemolytic reactions and prime recipients for severe acute reactions upon second exposure.

331
Q

Blood types

DEA 3 and 5

A

– have naturally occurring alloantibodies, and an immune response could be seen on the first transfusion

332
Q

Blood types

DEA 4

A

– unique in that approximately 99% of dogs are positive for DEA 4
– vast majority of dog transfusions are compatible for DEA 4 and do not show immune reactions
– universal donors can be DEA 4 positive or negative and still referred to as “universal” negative donors

333
Q

Blood types

neonatal isoerythrolysis

A

– a DEA 1‐negative female that has been sensitized to DEA 1 is bred to a DEA 1‐positive male. The pups that are born DEA 1 positive will likely experience a hemolytic reaction when nursing from the bitch as her colostrum contains anti‐DEA 1 antibodies
– hemolytic reaction begins as general lethargy and failure to thrive soon followed by death, and may be a component of fading puppy syndrome

334
Q

Blood types

Feline Blood Types

A

– type A, type B, or type AB
– type A is most common blood type

335
Q

Blood types

Type A cats

A

– have naturally occurring anti‐B antibodies
– anti‐B alloantibodies are fairly weak in affinity and low in titer level, causing a mild or delayed hemolytic reaction

336
Q

Blood types

Type B cats

A

– have very strong anti‐A alloantibodies and type B cats transfused with type A blood will have an acute and severe hemolytic reaction, often leading to death of the recipient

337
Q

Blood types

Type AB cats

A

– do not have any alloantibodies as they have both the A and B antigens present on their red cells, and are able to receive type A and type B red blood cell transfusions without consequence

338
Q

Blood types

Mik antigen

A

— another feline blood group described in 2007 when incompatible cross‐match results were seen between AB type‐matched blood
– Cats lacking expression of the Mik antigen can have naturally occurring antibodies against it, leading to acute hemolytic transfusion reaction upon mismatch

339
Q

Blood types

cross‐matching should always be performed in the following circumstances:

A
  1. patient had a previous transfusion more than four days before
  2. patient is a cat. Cats have naturally occurring antibodies against the AB group antigens they do not express.
  3. patient is a breeding animal; reduce the risk of neonatal isoerythrolysis
  4. patient’s transfusion history is unknown
340
Q

Blood types

Canine Blood Donors

A

– ages of one and eight years of age
– 25kg or more
– free of parasites and infectious disease
– HW free
– 11–19 mL/kg of blood can be safely taken from dogs with minimal signs of hypovolemia
– A donation frequency of every 8–12 weeks is therefore recommended to minimize detrimental effects and donation fatigue

341
Q

Blood types

Feline Blood Donors

A

– ages of one and eight years old
– be at least 5 kg in weight
– safely donate 10–15 mL/kg in a single donation
– often taken every 6–8 weeks
– cats more susceptible to hypotension and routine subcutaneous fluids at a volume of 2–3 times the blood volume removed are given

342
Q

Handling of Fresh Whole blood

A

– FWB may be held at room temperature (20°C−22°C) for up to 24 hours with no deleterious effects on RBC or PLT recovery and survival and plasma functionality

343
Q

Blood components

Cryoprecipitate vs Cryo‐poor plasma

A

Cyroprecip: contains Factor VIII, fibrinogen, vWF, no plasma protiens or non-liable factors
Cryo-poor: All Liable factors, vitamin K‐dependent clotting factors, EXCEPT VIII, XIII, and fibrinogen, contains non-liable factors and plasma protiens; LACKS vWF

344
Q

Storage duration for Cryoprecip/ Cryopoor

A

12 months

345
Q

Blood components

FFP vs Frozen Plasma

A

FFP: plasma portion of whole blood that has been separated from the RBCs via centrifugation and subsequently frozen twithin eight hours of collection
– contains Liable and Non-Liable factors, and Plasma proteins
Frozen Plasma: Plasma separated from whole blood and frozen within 24 hours
– ONLY contains Non-Liable factors and plasma proteins

346
Q

Storage duration for FFP

A

1yr, then is considered FP which can last up to 5 years

347
Q

Blood components

Platelet viability

A

– almost immediately begin to lose viability and function when refrigerated, with a 50% decrease occurring within the first 12–18 hours.
– after 72 hours, platelets are no longer present

348
Q

Blood components

Labile clotting factors

A

– factors V, VIII, and von Willebrand factor (vWf)

349
Q

blood components

non‐labile clotting factors

A

– factors II, VII, and X

350
Q

Blood components

Storage time for pRBCs

A

– can vary from 35 to 42 days, depending on the type of anticoagulant and nutrient solution used

351
Q

Blood components

Plasma proteins in FFP

A

plasma proteins = albumin and globulin

352
Q

Blood components

Platelet Products

A

– transfusions as fresh platelets in platelet‐rich plasma (PRP) or platelet concentrate (PC), cryopreserved platelets, or lyophilized platelets
– Fresh platelets have a shelf‐life of five days at room temperature
– Cryopreserved platelets can be stored up to six months at –20 °C but have low recovery (49% in dogs)
– Lyophilized platelets can be stored up to two years at 4 °C but their lifespan is observed to be only minutes

353
Q

Blood components

Ideal filter for blood transfusions

A

– gravity drip with a 170–260 µm filter

354
Q

Transfusion medicine

acute hemolytic transfusion reaction (AHTR)

A

– can be immunological vs non-immunological
– occurs within the first 30–60 minutes of the transfusion but can occur up to 24 hours after administration
– reaction is severe in felines
– retreatment with antihistamines and/or corticosteroids will not prevent a hemolytic reaction as they do not acutely suppress the production of IgG or IgM antibodies or prevent binding of IgE to mast cells

355
Q

Nonimmunologic HTRs

A

– occur due to thermal, osmotic, mechanical, or chemical factors that damage transfused RBCs, causing acute or delayed hemolysis
– Ex vivo cellular damage may occur prior to transfusion with improper or prolonged storage or bacterial contamination

356
Q

Immunologic transfusion reactions

A

– involve antigen–antibody reactions. The quantity and ability of an RBC antigen to provoke an immune response and the anti-RBC alloantibody response determine the consequences of potential RBC incompatibilities
– type II hypersensitivity reactions that occur due to major or minor RBC incompatibility

357
Q

Transfusion medicine

Delayed hemolytic transfusion reactions (DHTRs)

A

– occur more than 24 hours after the transfusion and commonly 3–5 days post transfusion
– antibody production within the recipient as a result of the presence of foreign antigens in the donor cells
– steady decrease in posttransfusion PCV over a period of 3–5 days, development of jaundice, fever, and anorexia

this is a non-infectious, immunological vs non-immunological reaction

358
Q

Tranfusion Medicine

Immune Complex Formation; Type III hypersensitivity

A

– formation and depositing of immune complexes in areas such as the glomeruli, endothelial cells, lymph nodes, and synovium,
– can lead to neutrophil migration, activation, and inflammation resulting in glomerulonephritis, vasculitis, lymphadenitis, and immune‐mediated arthritis within hours to weeks of exposure
– use of protein concentrates such as human serum albumin is suspected to cause type III hypersensitivity

359
Q

Transfusion Medicine

transfusion‐related acute lung injury (TRALI)

A

– Non‐cardiogenic pulmonary edema unrelated to circulatory overload during or hours after a transfusion
– caused by activation of neutrophils in pulmonary capillaries leading to vascular damage and pulmonary edema
– Clinical signs include respiratory distress, fever, tachycardia, and hypotension accompanied by pulmonary infiltrates

Type I and Type II

360
Q

What is TRALI most commonly associated with?

A

most commonly associated with high-plasma-volume transfusion products, although all transfusion products carry a risk

361
Q

Type 1 TRALI

A

– patients who have no concomitant risk factors for acute respiratory distress syndrome

362
Q

type II TRALI

A

reserved for those with acute respiratory distress syndrome (ARDS) risk factors or those that have existing mild ARDS and their respiratory status deteriorates in association with transfusion

363
Q

Tranfucsion Medicine

Transfusion‐associated circulatory overload (TACO)

A

– common non‐immunological transfusion complication.
acute respiratory distress secondary to increased circulatory volume from transfusion product administration and consequent hydrostatic pulmonary edema
– Volume overload (hypervolemia) can occur from transfusing too much product or transfusing it too rapidly
– can occur within 6 hours of transfusion

364
Q

Transfusion Medicine

Citrate Toxicity

A

– Citrate is normally metabolized by the liver but in large‐volume infusions of blood products, the metabolic pathway can be overwhelmed, leading to increased plasma citrate concentration and subsequent hypocalcemia
– Pts with liver failure at higher risk

365
Q

Tranfusion Medicine

Hyperammonemia

A

– When RBCs within the unit become inactive and die, they are broken down and release potassium and ammonia as a byproduct
– As units approach their expiry date, the bag contains a higher amount of ammonia and inactive RBCs than fresher units
– hyperammonemia can possibly develop in animals with underlying hepatic disease as they are unable to fully filter out ammonia

366
Q

Tranfusion Medicine

Transfusion‐related immunomodulation (TRIM)

A

– refers to the proinflammatory and immunosuppressive effects that blood transfusions can have on a patient incited by transfused mediators, proteins, and cells involved in the immune system

367
Q

thrombopoietin

A

– produce by the liver
– regulates the number of platelets circulating in the body

368
Q

What is the life span of platelets?

A

5-7 days

369
Q

Clotting Factor I

Which pathway?

A

Fibrinogen
– Common pathway

370
Q

Clotting Factor II

Which Pathway?

A

Prothrombin
– Common Pathway
– Vit K dependent

371
Q

Clotting Factor III

Which pathway?

A

Tissue factor
– Extrinsic pathway

372
Q

Clotting Factor IV

A

Calcium
– acts as binding agent for Vit K dependent factors

373
Q

Clotting Factor V

Which pathway?

A

Proaccelerin
– Common pathway

374
Q

Clotting Factor VI

A

Accelerin

375
Q

Clotting Factor VII

Which pathway?

A

Proconvertin
– Intrinsic/Extrinsic pathway
– Vit K dependent

376
Q

Clotting Factor VIII

Which pathway?

A

Antihemophilic factor A
– Intrinsic pathway

377
Q

Clotting Factor IX

Which Pathway?

A

Christmas factor, antihemophilic factor B
– Intrinsic pathway
– Vit K dependent

378
Q

Clotting Factor X

A

Stuart–Prower factor
– Start of Common pathway
– Vit k dependent

379
Q

Clotting Factor XI

Which pathway?

A

Plasma thromboplastin antecedent
– Intrinsic pathway

380
Q

Clotting Factor XII

Which pathway?

A

Hageman factor
– Intrinsic pathway

381
Q

Clotting Factor XIII

A

Fibrin stabilizing factor
– Result is fibrin clot
end of clotting cascade

382
Q

What intiates the Extrinsic Pathway?

A

– TF becomes exposed after tissue injury
– Once exposed it binds to Factor VII
– Ultimately forms Thrombin that intiates Extrinsic pathway

383
Q

Tissue Factor (TF)

Which pathway?

A

Factor III
– Extrinsic pathway
– transmembrane glycoprotein

384
Q

Major crossmatches evaluate:

A

major crossmatch is designed to test the compatibility between donor RBCs and recipient plasma.

385
Q

Minor Crossmatches evaluate:

A

minor crossmatch is designed to test compatibility between donor plasma with recipient RBCs.

386
Q

febrile nonhemolytic transfusion reaction (FNHTR)

A

– characterized by a temperature over (102.5°F) with an increase in temperature > (1.8°F) from the pretransfusion temperature that occurs during or within 4 hours of the completion of a transfusion.
– other etiologies of hyperthermia must be ruled out such as external warming, underlying patient condition or infection, or other transfusion reactions
– most common transfusion reaction in veterinary medicine.
– classically mild and self-limiting

387
Q

TRALI mechanisms

A

– antibodies (i.e., antibodies to human leukocyte antigen class I and II),
various neutrophil antigens,
lipids,
soluble CD40 ligand

have all been associated with the development of TRALI

– patients that already have primed neutrophils and endothelium from their underlying condition (“first hit”),
– and the transfusion becomes the “second hit” activating those neutrophils

388
Q

Transfusion medicine

Storage lesion

A

– During the storage of RBCs, biomechanical, biochemical, and immunologic changes occur that may adversely affect the RBCs and the recipient
– may affect the viability, deformability, and oxygen carrying capacity of transfused RBCs as well as the microcirculatory flow and immune response in the recipient
–In veterinary medicine, there is evidence of increased in vivo hemolysis with transfusion of stored versus fresher RBCs in multiple canine studies

389
Q

Mechanisms of Endothelium that prevents clotting under normal conditions:

x7

A
  1. smooth, non-thrombogenic surface
  2. Vasodilation - harder for plts to aggregate
  3. Endothelial derived vasodilators - N.O.
  4. PGI2 = Prostacyclin “keeps blood cyclin”
  5. Secretes heparin like molecules
  6. Expresses Thrombomodulin - modulates thrombin
  7. t-PA - plminogen to plasmin to destroy clots